Juvenile dermatomyositis, a rare but often severe and chronic systemic autoimmune disease, includes a large number of patients who are treatment resistant, requiring long term immunosuppressive therapy. A small study shows promise using a targeted biologic therapy called abatacept to treat such patients.
Abatacept therapy offers promising results treating juvenile dermatomyositis
